350 related articles for article (PubMed ID: 36571557)
41. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation.
Maecker B; Jack T; Zimmermann M; Abdul-Khaliq H; Burdelski M; Fuchs A; Hoyer P; Koepf S; Kraemer U; Laube GF; Müller-Wiefel DE; Netz H; Pohl M; Toenshoff B; Wagner HJ; Wallot M; Welte K; Melter M; Offner G; Klein C
J Clin Oncol; 2007 Nov; 25(31):4902-8. PubMed ID: 17971586
[TBL] [Abstract][Full Text] [Related]
42. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.
Ganne V; Siddiqi N; Kamaplath B; Chang CC; Cohen EP; Bresnahan BA; Hariharan S
Clin Transplant; 2003 Oct; 17(5):417-22. PubMed ID: 14703923
[TBL] [Abstract][Full Text] [Related]
43. Identifying predictive factors for posttransplant lymphoproliferative disease in pediatric solid organ transplant recipients with Epstein-Barr virus viremia.
Weintraub L; Weiner C; Miloh T; Tomaino J; Joashi U; Benchimol C; Strauchen J; Roth M; Wistinghausen B
J Pediatr Hematol Oncol; 2014 Nov; 36(8):e481-6. PubMed ID: 24878618
[TBL] [Abstract][Full Text] [Related]
44. Risk factors for post-transplant lymphoproliferative disorder in pediatric patients: a case-control study.
Allen UD; Farkas G; Hébert D; Weitzman S; Stephens D; Petric M; Tellier R; Ngan B; Fecteau A; West L; Wasfy S
Pediatr Transplant; 2005 Aug; 9(4):450-5. PubMed ID: 16048596
[TBL] [Abstract][Full Text] [Related]
45. Lymphoproliferative disorders after renal transplantation along 2 decades: a large longitudinal study of 21.546 recipients.
Franco A; Hernandez D; Zarraga S; Fructuoso AS; Crespo M; Mazuecos A; Corte CD; Benot AR; Ruiz JC; Beneyto I;
Nefrologia (Engl Ed); 2023; 43(4):427-434. PubMed ID: 37813738
[TBL] [Abstract][Full Text] [Related]
46. Case Report: Non-negligible Epstein-Barr virus-associated posttransplant lymphoproliferative disorders in a lung transplant recipient.
Hu J; Yu YW; Han DS; Li XJ; Zhang YQ; Cai HL; Xiao YH; Zheng X
Front Immunol; 2023; 14():1244534. PubMed ID: 37781359
[TBL] [Abstract][Full Text] [Related]
47. CD30 expression and survival in posttransplant lymphoproliferative disorders.
Kinch A; Amini RM; Hollander P; Molin D; Sundström C; Enblad G
Acta Oncol; 2020 Jun; 59(6):673-680. PubMed ID: 32102582
[No Abstract] [Full Text] [Related]
48. Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder.
Holman CJ; Karger AB; Mullan BD; Brundage RC; Balfour HH
Clin Transplant; 2012; 26(5):741-7. PubMed ID: 22385033
[TBL] [Abstract][Full Text] [Related]
49. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
[TBL] [Abstract][Full Text] [Related]
50. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients.
Colombini E; Guzzo I; Morolli F; Longo G; Russo C; Lombardi A; Merli P; Barzon L; Murer L; Piga S; Ciofi Degli Atti ML; Locatelli F; Dello Strologo L
Pediatr Nephrol; 2017 Aug; 32(8):1433-1442. PubMed ID: 28280938
[TBL] [Abstract][Full Text] [Related]
51. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.
Hart M; Thakral B; Yohe S; Balfour HH; Singh C; Spears M; McKenna RW
Am J Surg Pathol; 2014 Nov; 38(11):1522-9. PubMed ID: 25007145
[TBL] [Abstract][Full Text] [Related]
52. Dynamics of Epstein-Barr virus on post-transplant lymphoproliferative disorders after antithymocyte globulin-conditioned allogeneic hematopoietic cell transplant.
Lindsay J; Othman J; Yong MK; Ritchie D; Chee L; Tay K; Tio SY; Kerridge I; Fay K; Stevenson W; Arthur C; Chen SC; Kong DCM; Greenwood M; Pergam SA; Liu C; Slavin MA
Transpl Infect Dis; 2021 Oct; 23(5):e13719. PubMed ID: 34453768
[TBL] [Abstract][Full Text] [Related]
53. Epidemiology of posttransplantation lymphoproliferative disorder in adult renal transplant recipients.
Morton M; Coupes B; Roberts SA; Klapper PE; Byers RJ; Vallely PJ; Ryan K; Picton ML
Transplantation; 2013 Feb; 95(3):470-8. PubMed ID: 23222821
[TBL] [Abstract][Full Text] [Related]
54. Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry.
Zimmermann H; Oschlies I; Fink S; Pott C; Neumayer HH; Lehmkuhl H; Hauser IA; Dreyling M; Kneba M; Gärtner B; Anagnostopoulos I; Riess H; Klapper W; Trappe RU
Transplantation; 2012 Mar; 93(5):543-50. PubMed ID: 22234349
[TBL] [Abstract][Full Text] [Related]
55. Epstein-Barr virus load in transplant patients: Early detection of post-transplant lymphoproliferative disorders.
Fellner MD; Durand KA; Solernou V; Bosaleh A; Balbarrey Z; García de Dávila MT; Rodríguez M; Irazu L; Alonio LV; Picconi MA
Rev Argent Microbiol; 2016; 48(2):110-8. PubMed ID: 27157146
[TBL] [Abstract][Full Text] [Related]
56. A Focused Review of Epstein-Barr Virus Infections and PTLD in Pediatric Transplant Recipients: Guidance From the IPTA and ECIL Guidelines.
Yamada M; L'Huillier AG; Green M
J Pediatric Infect Dis Soc; 2024 Feb; 13(Supplement_1):S31-S38. PubMed ID: 38417085
[TBL] [Abstract][Full Text] [Related]
57. Increased MYC expression without MYC gene translocation in patients with the diffuse large B-cell-lymphoma subtype of iatrogenic immunodeficiency-associated lymphoproliferative disorders.
Kabasawa N; Shiozawa E; Murai S; Homma M; Uesugi Y; Matsui T; Nakata A; Shimada S; Sasaki Y; Baba Y; Watanuki M; Arai N; Fujiwara S; Kawaguchi Y; Tsukamoto H; Uto Y; Yanagisawa K; Hattori N; Sakai H; Harada H; Nakamaki T; Takimoto M; Yamochi-Onizuka T
J Clin Exp Hematop; 2021; 61(3):120-125. PubMed ID: 34511544
[TBL] [Abstract][Full Text] [Related]
58. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
[TBL] [Abstract][Full Text] [Related]
59. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
Oertel S; Trappe RU; Zeidler K; Babel N; Reinke P; Hummel M; Jonas S; Papp-Vary M; Subklewe M; Dörken B; Riess H; Gärtner B
Ann Hematol; 2006 Jul; 85(7):478-84. PubMed ID: 16586109
[TBL] [Abstract][Full Text] [Related]
60. Identification of high-risk monomorphic post-transplant lymphoproliferative disorder following solid organ transplantation.
Voorhees TJ; Kannan KK; Galeotti J; Grover N; Vaidya R; Moore DT; Montgomery ND; Beaven AW; Dittus C
Leuk Lymphoma; 2021 Jan; 62(1):86-94. PubMed ID: 32933363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
